[Featured Stock] BioSmart Rises on MFDS Approval of 1-Hour COVID-19 Diagnostic Device
[Asia Economy Reporter Minwoo Lee] Biosmart's stock price is on the rise. The news that a diagnostic device capable of detecting COVID-19 within one hour has been approved by the Ministry of Food and Drug Safety appears to have acted as a positive factor.
As of 11:24 AM on the 24th, Biosmart's stock price recorded 6,710 KRW, up 6.85% from the previous day. This is because AMS Bio, which is 100% owned by Biosmart, received approval from the Ministry of Food and Drug Safety for its emergency COVID-19 diagnostic kit.
Hot Picks Today
"Do We Need to Panic Buy Again?" War Drives 30% Price Surge... Even the Bedroom Feels the Impact
- "Is a 10,000 KOSPI Breakthrough Possible?" Target Index Raised by 40%... Securities Firms Release Outlook [Weekend Money]
- "Contact Me First If Houses Are Built": Wealthy Clients Eyeing... Will Ultra-High-End Residences Worth 20 Billion Won Be Developed? [Real Estate AtoZ]
- "Anyone Who Visited the Room Salon, Come Forward"… Gangnam Police Station Launches Full Staff Investigation After New Scandal
- Trump's Remark on "Detailed Talks with Xi Jinping on Taiwan Arms Sales" Sparks Controversy... Taiwan Moves to Defuse Tensions (Comprehensive)
On the same day, the Ministry approved products from six companies including AMS Bio, Siseon Biomaterials, Micobiomed, Biomeri Korea, Jinex, and Cosmax Pharma. As a result, the total number of emergency screening diagnostic kits that can detect COVID-19 within one hour has increased to nine. All of these products use the real-time polymerase chain reaction (RT-PCR) method.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
